Preferred Label : MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1;
NCIt definition : A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient,
and a capsule implanted with a genetically modified allogeneic cell line that continuously
releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential
immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded
macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic
cell capsules and the autologous irradiated cells isolated from the patient's tumor
are co-localized in the patient's tissue. This permits the production of GM-CSF and
exposes the immune system to the tumor-associated antigens (TAA) expressed by the
autologous tumor cells at the injection site. Local expression of GM-CSF recruits
and activates antigen-presenting cells (APC), which induces both antibody-dependent
cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site
of the injection and systemically. This may lead to tumor regression. By using the
patient's own irradiated cancer cells as vaccine antigens, the patient's immune system
is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell
technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous
release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine,
is a strong immune booster and plays an important role in the activation of immune
system.;
Molecule name : MVX-ONCO-1;
NCI Metathesaurus CUI : CL474106;
Origin ID : C123382;
UMLS CUI : C4053612;
Semantic type(s)
- concept_is_in_subset
